Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 1
1995 4
1996 3
1997 7
1998 7
1999 12
2000 29
2001 33
2002 50
2003 51
2004 92
2005 96
2006 129
2007 114
2008 130
2009 147
2010 135
2011 158
2012 157
2013 169
2014 190
2015 214
2016 183
2017 192
2018 204
2019 185
2020 201
2021 182
2022 171
2023 137
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

3,009 results

Results by year

Filters applied: . Clear all
Page 1
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Gagliardi M, et al. Sci Rep. 2020 May 22;10(1):8537. doi: 10.1038/s41598-020-65250-3. Sci Rep. 2020. PMID: 32444778 Free PMC article.
We hypothesized that ERK2, but not ERK1, promotes the cancer stem cell (CSC) phenotype and metastasis in TNBC. Stable knockdown clones of the ERK1 and ERK2 isoforms were generated in SUM149 and BT549 TNBC cells using shRNA lentiviral vectors. ...
We hypothesized that ERK2, but not ERK1, promotes the cancer stem cell (CSC) phenotype and metastasis in TNBC. Stable knockdown clone …
Integration of data from the cell-based ERK1/2 ELISA and the Comparative Toxicogenomics Database deciphers the potential mode of action of bisphenol A and benzo[a]pyrene in lung neoplasm.
Stanic B, Samardzija Nenadov D, Fa S, Pogrmic-Majkic K, Andric N. Stanic B, et al. Chemosphere. 2021 Dec;285:131527. doi: 10.1016/j.chemosphere.2021.131527. Epub 2021 Jul 14. Chemosphere. 2021. PMID: 34329126
Experimental data on ERK1/2 activation were derived from the cell-based phospho-ERK1/2 ELISA on human alveolar epithelial cells A549. A549 cells were exposed to bisphenol A (BPA), benzo[a]pyrene (BaP), tributyltin (TBT), and ibuprofen from 10(-12) M to 10(-5) M. Res …
Experimental data on ERK1/2 activation were derived from the cell-based phospho-ERK1/2 ELISA on human alveolar epithelial cell …
Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y, Ye X, Chen R, Gao Q, Zhao D, Ling C, Qian Y, Xu C, Tao M, Xie Y. Zhao Y, et al. Oncol Rep. 2020 Sep;44(3):959-972. doi: 10.3892/or.2020.7672. Epub 2020 Jul 7. Oncol Rep. 2020. PMID: 32705247 Free PMC article.
However, the effects and the clinical significance of SIRT7 in human lung cancer is largely unknown. The present research demonstrated that SIRT7 was increased in human lung cancer tumor tissues. SIRT7 upregulation was associated with clinicopathological characteris …
However, the effects and the clinical significance of SIRT7 in human lung cancer is largely unknown. The present research demonstrate …
Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. Wang M, et al. J Chemother. 2013 Jun;25(3):162-9. doi: 10.1179/1973947812Y.0000000056. J Chemother. 2013. PMID: 23783141
Extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt are two major cell survival pathways that are upregulated and activated in lung cancer tissues. ...In the present study, we aimed to determine whether the ERK1/2 and Akt pathways contribute to cisplat …
Extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt are two major cell survival pathways that are upregulated and activated in …
Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer.
Zhao S, Qiu ZX, Zhang L, Li WM. Zhao S, et al. Tumour Biol. 2015 Jun;36(6):4143-50. doi: 10.1007/s13277-015-3048-4. Epub 2015 Jan 18. Tumour Biol. 2015. PMID: 25596700
The extracellular-regulated kinase (ERK) 1/2, as a member of the mitogen-activated protein kinase family, plays a crucial role in the development of cancer. However, little is known about the prognostic value of ERK1/2 and phosphorylated ERK1/2 (p-ERK1/2) in …
The extracellular-regulated kinase (ERK) 1/2, as a member of the mitogen-activated protein kinase family, plays a crucial role in the develo …
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Ward RA, Anderton MJ, Bethel P, Breed J, Cook C, Davies EJ, Dobson A, Dong Z, Fairley G, Farrington P, Feron L, Flemington V, Gibbons FD, Graham MA, Greenwood R, Hanson L, Hopcroft P, Howells R, Hudson J, James M, Jones CD, Jones CR, Li Y, Lamont S, Lewis R, Lindsay N, McCabe J, McGuire T, Rawlins P, Roberts K, Sandin L, Simpson I, Swallow S, Tang J, Tomkinson G, Tonge M, Wang Z, Zhai B. Ward RA, et al. J Med Chem. 2019 Dec 26;62(24):11004-11018. doi: 10.1021/acs.jmedchem.9b01295. Epub 2019 Nov 25. J Med Chem. 2019. PMID: 31710489
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma. We describe our structure-based design approach leading to the di …
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK …
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
Vicent S, López-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchón C, Quero C, Soria JC, Martín-Algarra S, Manzano RG, Montuenga LM. Vicent S, et al. Br J Cancer. 2004 Mar 8;90(5):1047-52. doi: 10.1038/sj.bjc.6601644. Br J Cancer. 2004. PMID: 14997206 Free PMC article.
Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC). The purpose of this study was to characterise the extent of the activation of ERK1/2 by immunohistochemistry in patients with NSCLC, and to determine the relationship of …
Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC). The purpose of this study was to cha …
Distribution of ERK1/2 and ERK3 during normal rat fetal lung development.
Kling DE, Brandon KL, Sollinger CA, Cavicchio AJ, Ge Q, Kinane TB, Donahoe PK, Schnitzer JJ. Kling DE, et al. Anat Embryol (Berl). 2006 Mar;211(2):139-53. doi: 10.1007/s00429-005-0063-z. Epub 2005 Dec 22. Anat Embryol (Berl). 2006. PMID: 16374608
To characterize this variability in greater detail, the temporal and spatial distributions of activated ERK1/2 and ERK3 during rat fetal lung development were investigated. The diphosphorylated (activated) forms of ERK1/2 (dp-ERK1/2), ERK3, and its pho …
To characterize this variability in greater detail, the temporal and spatial distributions of activated ERK1/2 and ERK3 during rat fe …
Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling.
Ding C, Tang W, Fan X, Wang X, Wu H, Xu H, Xu W, Gao W, Wu G. Ding C, et al. Cell Death Dis. 2018 Jul 23;9(8):802. doi: 10.1038/s41419-018-0817-1. Cell Death Dis. 2018. PMID: 30038287 Free PMC article.
Moreover, PEAK1 upregulation markedly enhanced the activation of extracellular signal-regulated kinase-1/2 (ERK1/2) and Janus kinase-2 (JAK2) signaling in lung cancer cells. ...Our findings highlight a newer mechanism for PEAK1 in regulating EMT and metastasis in …
Moreover, PEAK1 upregulation markedly enhanced the activation of extracellular signal-regulated kinase-1/2 (ERK1/2) and Janus kinase- …
Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-kappaB pathway in LPS-induced acute lung injury.
Li TJ, Zhao LL, Qiu J, Zhang HY, Bai GX, Chen L. Li TJ, et al. Mol Med Rep. 2017 Aug;16(2):2225-2232. doi: 10.3892/mmr.2017.6837. Epub 2017 Jun 21. Mol Med Rep. 2017. PMID: 28656298
Interleukin (IL)-17 has been implicated in a variety of inflammatory lung diseases. However, little is known about the expression and biological role of IL-17 in acute lung injury (ALI). ...Of note, blockade of IL-17 effectively inhibited LPS-induced expression and …
Interleukin (IL)-17 has been implicated in a variety of inflammatory lung diseases. However, little is known about the expression and …
3,009 results